Objectives: To identify and analyse existing evidence from published studies evaluating the efficacy and safety of a percutaneous vessel closure device for the closure of large arterial femoral arterial access sites (!10 French). Design: This study was a systematic literature review and meta-analysis. Materials and methods: Electronic databases were searched for studies published on the evaluation of the Prostar XL vessel closure device. There was no restriction by study design or patient population. Appraisal of studies for inclusion and data extraction were performed independently by two reviewers. Meta-analysis was performed where feasible. Results: Twenty-one studies were included, which reported data specifically for closure of large (!10 Fr) femoral arterial access sites using the Prostar XL device. The Prostar XL device, used for closure of these large femoral artery access sites, had a high rate of procedural success equal to that reported for closure by femoral artery surgical cut-down. There was evidence for reduced procedural time, time to discharge and time to ambulation. Complication rates were lower, but not significantly so, with Prostar XL vs. surgical cut-down.
Introduction
Haemostasis of small femoral arterial access sites (<8 French) can be achieved via manual compression at the vascular access site. Manual compression is associated with a need for extended bed rest, involving patient discomfort, resource use and cost implications, and, therefore, a number of vascular closure products now exist for the closure of small (5e8 Fr) femoral arterial access sites, including collagen plugs (Angioseal, St Jude Medical, St Paul, MN, USA); balloon-positioning catheters (Duett, Vascular Solutions, Minneapolis, MN, USA); clip-based closure (StarClose SE, Abbott Vascular, Santa Clara, CA, USA); sealing agents (Mynx, AccessClosure, Mountain View, CA, USA); and sutures for placement around the femoral artery (Prostar XL Percutaneous Vascular Surgical Device, Perclose ProGlide Suture-Mediated Closure System, Abbott Vascular, Santa Clara, CA, USA). 1 These vascular closure devices have been primarily developed for peripheral interventions. Endovascular exclusion of abdominal aortic aneurysms (AAAs), thoracic aortic aneurysms (TAAs) and percutaneous aortic valve replacement use larger (12e24 Fr) sheaths at the insertion site for their delivery system (most frequently the common femoral artery (CFA)). A totally percutaneous access to the CFA for endovascular procedures would potentially avoid the complications of a groin cut-down to access the femoral artery and therefore accelerate patient discharge, thus limiting the overall in-hospital cost.
The primary aim of this article was to determine the efficacy and safety of the Prostar XL device (Abbott Vascular, Santa Clara, CA, USA), the only CE Mark-approved percutaneous vascular surgical device for closure of large-size (!10 Fr) femoral arterial punctures. 2 The Prostar XL is designed for the repair of femoral artery puncture sites using sheaths ranging from 8.5 Fr to 10 Fr. In 2009, CE Mark approval and Canada Health approval was obtained to treat puncture sites up to and including 24 Fr, and it has been reported in the literature to treat puncture sites using sheaths ranging from 8.5 to 24 Fr. Where available, data comparing femoral artery surgical cut-down with the use of the Prostar XL system to close femoral artery access sites (technical success, procedural time and patient recovery times) were analysed. To close femoral artery access sites greater than 10 Fr, a 'preclose' technique is used whereby the sutures of the Prostar XL device are placed at the arteriotomy at the beginning of an intervention without tying the knots down to the arterial surface. The technique is described in detail in the International IFU for the Prostar XL Percutaneous Vascular Surgical System. 2 At the end of the case, after withdrawal of large bore sheaths and while the guidewire is in place, the knots are advanced to the arteriotomy. When haemostasis is confirmed, the guidewire may be removed.
Methods

Data sources
Medline and EMBASE (using the Ovid interface) and the Cochrane Central Trials Register were searched for studies published between 1 January 1995 and 1 May 2009 that involved the use of vascular closure devices in patients of any age and gender requiring suture-mediated closure of large femoral arterial access sites, irrespective of the comparator device or method used. The search strategy used for Medline is shown in Table 1 .
Citations detected by the literature search were initially screened on the basis of their abstracts. Fulltexts were obtained for all citations that could potentially meet the eligibility criteria and were again screened.
Inclusion criteria
Studies reporting use of a device for closure of femoral arterial punctures of size 10 Fr and above were included. All patient populations were included, regardless of surgical procedure. Randomised controlled trials (RCTs), non-randomised controlled trials, observational studies, case-series and case reports were included. Reviews, editorials and letters were excluded. Only English-language publications were included. 
Data extraction
Data from included studies were extracted. Two independent reviewers extracted each study in parallel; following this, each pair of extraction grids was compared and any differences were reconciled by a third, independent reviewer. Where more than one publication was identified describing a single study, the data were compiled into a single entry in the data extraction table. Endpoints extracted were: proportion of procedural successes as measured by patients; proportion of procedural successes as measured by access site closures; total procedural time; time to ambulation; time to discharge; incidence of complications (as a whole); incidence of haemorrhage; incidence of haematoma; transfusion requirement; and costs. Definitions of each outcome were according to individual study; there is therefore the possibility that these definitions may have differed between studies, but, in the absence of comprehensive information on outcome definition, this was considered the best method to extract the data available. For example, studies may have differed in definition and reporting of 'complications', but as there is no standard measurement of what constitutes a complication, extracting data from all studies reporting this outcome was deemed the most valid method. Where possible, the outcome definition was also extracted to aid interpretation of the data.
All study designs were incorporated in the review to include all possible relevant evidence on the Prostar XL. Unfortunately, a large proportion of the available evidence comes from small-scale and uncontrolled studies.
Where possible, meta-analysis of comparative data was performed to analyse the efficacy and safety of the Prostar XL compared with open surgical cut-down. In addition, we also pooled data from non-comparative studies (i.e., studies that only presented data for the Prostar XL), to provide a pooled estimate of event rates with the Prostar XL. While the latter analysis is somewhat limited and does not provide information to compare the Prostar XL with surgical cutdown, given the relative lack of comparative studies this analysis was performed to synthesise all relevant studies to provide the fullest possible picture of the efficacy and safety of the Prostar XL. Meta-analysis was performed using Stata Ò statistical software (Intercooled version 9.2 for Windows) using the metan version 9 add-in. 3 Effect sizes for dichotomous outcomes were presented as risk ratios, and effect sizes for continuous outcomes as the weighted mean difference between treatments. Fixed-effects estimates were calculated according to the ManteleHaenszel model, and random-effects estimates according to the method of Der-Simonian and Laird. Due to the variation between studies in terms of design and patient population, it was judged that the greater degree of between-study heterogeneity assumed in the random-effects model was more suitable for the data being analysed; and, hence, random-effects analyses are presented here. I-squared values were calculated as a measurement of heterogeneity and typically indicated a relatively high degree of heterogeneity, supporting the use of random-effects analysis.
The review was conducted and reported in line with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, the most current guidelines extant on systematic review methodology (the initial set-up of the review followed the earlier quality of reporting metaanalyses standards (QUOROM) guidelines; following publication of the PRISMA guidelines in July 2009, the review was reported in accordance with PRISMA). 4 
Results
The flow of studies through the review according to PRISMA guidelines is shown in Fig. 1 . A total of 729 studies were retrieved from searching the literature databases; after a review of abstracts, 204 full-text citations were obtained for detailed evaluation. This resulted in 20 studies, which met the inclusion criteria for this review and provided data specifically for use of the Prostar XL device to close femoral arterial access sites of size !10 Fr. There were only seven studies, which compared the use of the Prostar XL with femoral arterial surgical cut-down. These studies are summarised in Table 1 .
The included studies consisted of one RCT and 19 observational studies published between 1999 and 2009. These studies ranged in size from one patient in a case report 5 to 189 patients in one observational study, 6 but, in general, were relatively small, uncontrolled studies; and these limitations should be kept in mind when interpreting the evidence. The majority of studies (15) were based in the USA. By far the most common procedure evaluated was AAA, investigated by 11 studies, with a further six studies investigating endovascular treatment of aneurysms in general and included patients with TAAs as well as AAA (Table 1) .
Meta-analysis was performed where feasible; a summary of all meta-analysis results is provided in Table 2 .
Efficacy
Rate of procedural success (access site)
Twelve included studies reported the success rate in terms of the number of access sites closed. 5À16 Success rates for the Prostar XL varied from 64.4% 6 e100%. 9 Definitions of success were broadly similar between studies: mainly, the definition of success was adequate haemostasis without requirement for surgical cut-down, although one study also required no complications requiring medical or surgical intervention within 30 days. 12 Only one study compared the Prostar XL with surgical cut-down: very high rates of success (>90%) were achieved with both approaches, where success was defined as percutaneous closure of the arteriotomy without any locoregional complications requiring medical therapy or surgical conversion within 30 days of the procedure. 12 The weighted average success rate (95% confidence interval (CI)) from the studies, which provided data specifically for the Prostar XL, was calculated as 91% (87e95%). 5À16
Rate of procedural success (patients)
Sixteen of the included studies reported the success rate in terms of the number of patients in whom successful closure was achieved. 5,7À12,14À22 Two observational studies compared success rates with the Prostar XL to surgical cutdown; rates were approximately equal in both arms. 12, 20 In the first study, success was defined via completion angiography demonstrating apposition of stentgrafts to the aortic wall, normal perfusion of the aortic branches and exclusion of the aortic transection without evidence of extravasation; success rates were 100% in both arms (N Z 7 for surgical cut-down, N Z 4 for Prostar XL). In the second study, success was defined as closure with the absence of any loco-regional complication requiring medical treatment or surgical intervention within 30 days of surgery (N Z 21 for surgical cut-down, N Z 19 for Prostar XL).
Across all studies reporting this outcome, successful arterial closure was achieved in between 53% 15 and 100% of patients using the Prostar XL device. 5, 9, 18, 20 The article by Traul 15 described their "initial experience" with the preclose technique with a success rate of 53%, and "A detailed look at reasons for device failure has proven helpful in revising our techniques and informing others about the potentials problems with this technique." 15 Meta-analysis of data from all studies reporting success rates for the Prostar XL provided a pooled estimate of 89% (84e94%; random-effects analysis). 5,7e12,14e22 Total procedural time Ten of the included studies present data relating to the total procedure time. 7,8,10À13,15,18,19,22 Six of those studies compared femoral artery access site closure using the Prostar XL to femoral arterial surgical cut-down; mean total procedural times are shown in Table 4 .
Meta-analysis of the three studies, which provided data in a form suitable for meta-analysis (provided patient numbers, mean and standard deviation or CIs), was performed. The analysis found that there was a significant reduction in total procedural time with the Prostar XL compared with surgical cut-down. 11, 19, 22 This difference was approximately 1 h. The random-effects meta-analysis identified a weighted mean difference of 62.4 min (27.8e97.1 min) (Fig. 2) .
In addition to the meta-analysed studies, Morasch reported significant reductions in procedural times with the Prostar XL compared with surgical cut-down and also noted a significant reduction in total anaesthesia time and in the use of general anaesthesia. 23 By contrast, Jean-Baptiste reported no significant difference in mean surgical time between the Prostar XL and surgical cut-down, 12 while Borner reported no significant difference in median procedural time for the same comparison. 8 Time to discharge Eleven of the included studies reported data relating to the time to discharge. 5,8,10À13,18,19,21,23 Overall, the mean time to discharge with the Prostar XL ranged from 1 day 11 to 7 days. 21 Four studies compared the Prostar XL to surgical cutdown for this outcome, although data were not reported in a way, which allowed meta-analysis. 8, 12, 19, 23 In all four, time to discharge was less in the Prostar XL group, with reductions ranging from 0.4 23 to 8.5 days. 19 The reduction was significant in only one of the four studies. 19 Time to ambulation Four of the identified studies presented data relating to the time to ambulation. 5,22À24 Mean time to ambulation varied from 0.17 24 to 0.84 days 22 for the Prostar XL. Two studies compared the Prostar XL to surgical cut-down for this outcome. Notably, the RCT by Torsello found a mean time to ambulation of 20 h in the Prostar XL group compared with 33 h in the group receiving surgical closure, 22 a significant reduction of 40% (p < 0.001). By contrast, the observational study by Morasch reported similar times to ambulation (0.8 days) in both patients receiving surgical cut-down and patients in whom the Prostar XL device was used. 23 Metaanalysis of these two studies was not possible.
It should be noted that the time to discharge/ambulation is determined by the unblinded surgeon, and is therefore susceptible to bias.
Safety Complication rate
Sixteen included studies reported data relating to complication rates. 5,7,9,11À22,24 The defined complications varied between individual studies, limiting synthesis of the data to those studies with comparable definitions.
Five studies compared complication rates with the Prostar XL to complication rates for surgical cut-down. Four of these were suitable for meta-analysis (in the fifth study, complication rates were zero in both arms). 20 The risk ratio for the Prostar XL compared with surgical cut-down is 0.87 (0.41e1.88), suggesting a lower risk with the Prostar XL (not statistically significant). Similarly, individual studies indicated a reduction in complication rates with the Prostar XL but these were not significant and further studies are needed to explore this. 6, 22, 23 A range of different complications is taken into account when complications rates are reported, and it is important to note that the different complications differ in severity. For example, the Prostar XL may be associated with increased bleeding events, particularly in obese patients, 7, 13, 14, 22 with lower rates of complications such as lymph leak and lymphoceles, which can be experienced with cut-down. 12, 22 Severe long-term complications may also occur less frequently with the Prostar XL than with cut-down. 7 V6134.6 V7503.6 0.31 Figure 2 Procedural time random-effects meta-analysis.
Rate of haemorrhage
Nine of the included studies reported data relating to the rate of haemorrhage. 9,11,12,14,15,18,22À24 Quoted rates of haemorrhage observed with the Prostar XL varied from 0% 11, 18 to 14.9%. 23 Only one study compared the Prostar XL to surgical cutdown; this was the RCT by Torsello, which reported that one patient in the Prostar XL group required arterial suturing of the access artery due to bleeding, whereas none of the patients in the surgical cut-down arm experienced haemorrhage. 22 In this case, the guidewire was previously removed, which is not standard procedure described in the preclose technique, and temporary haemostasis could not be achieved with a catheter balloon. None of the comparative observational studies reported haemorrhage rates for both the Prostar XL and surgical cut-down.
Rate of haematoma
Nine of the identified studies present data relating to the rate of haematoma. 5,7,9À11,13,17,18,23 Rates of haematoma varied from 0% reported in a number of studies 5,9À11,13,17,18 to 4.5% in the study by Arthurs. 7 Only one study compared the Prostar XL with surgical cut-down 23 ; there was no clear difference in haematoma rate between the two arms (4.3% with Prostar XL; 5.7% with surgical cut-down).
Rate of transfusion
Six of the identified studies present data relating to the rate of transfusion. 7, 11, 15, 19, 22, 23 Torsello reported that no patient received transfusion in either the Prostar XL or the surgical cut-down group. 22 Two observational studies compared the Prostar XL to surgical cut-down. 19, 23 In one study, the rates of transfusions were reported both for the index hospitalisation and as secondary to access-site complication, and were similar in both groups. 23 In the second study, the Prostar XL used in percutaneous endovascular surgery was compared with open vascular surgical repair of ruptured AAAs, and, therefore, the two groups are not comparable in terms of transfusion requirements. 19 The other studies were non-comparative. In general, there was considerable variation in the rate of transfusion, from 0% 11 to over 50% in the study by Traul. 15 The high value recorded may be because this study recorded transfusions during the entire hospitalisation period as opposed to only during the surgical procedure. The authors compared this to their prior experience with open surgical cut-down of the femoral artery access site, where the transfusion rate was generally lower (28%).
Costs
The study by Jean-Baptiste was conducted in France, and reported costs for the Prostar XL compared with surgical cut-down. 12 The total cost including hospitalisation cost and the use of the device was lower in the Prostar XL group (V6134.60 per patient) compared with the surgical cutdown group (V7503.60 per patient; Table 3 ). This was not significant (p Z 0.31). Hospitalisation costs, not including the cost of the device, were however significantly lower in the Prostar XL group (V5579.60 vs. V7503.60, p Z 0.04). Although there was no significant difference in total costs, the data suggest it is possible that the savings in hospitalisation cost associated with the Prostar XL may be able to compensate for the additional cost of the device. 12 The RCT reported by Torsello, conducted in Germany, also reported costs as an outcome. The cost of materials in the Prostar XL group was significantly higher compared with the surgery arm, but the cost for operating time use was significantly reduced (V251 vs. V357.6). The overall cost was V99 higher in the percutaneous Prostar XL group, mainly due to the cost of the device. 22 
Discussion
Only one device, the Prostar XL Percutaneous Vascular Surgical Device, was identified in use for closure of large (!10 Fr) femoral arterial access sites. This is as expected, as this is currently the only device indicated for such use. The Prostar XL device was associated with a rate of procedural success equivalent to that observed with surgical cut-down, as measured by access site or patients. Therefore, this device is shown to be as effective as surgical cut-down. (Table 5) Meta-analysis and results of individual studies suggest that the Prostar XL was associated with a statistically significant reduction in total procedural time of approximately 1 h. Given the serious nature of the procedures in which the Prostar XL is used (most commonly, endovascular repair of AAA in the studies in our review), if such a reduction is possible, it is likely to be clinically meaningful and may potentially even have implications for improved patient safety. This finding is in line with two recent meta-analyses, which demonstrate a significant reduction in time to haemostasis/total operative time with vascular closure devices. 25, 26 Reductions in total surgical procedural time could also have implications for operating theatre throughput. There are a number of factors, which affect throughput in theatres and, therefore, if the Prostar XL is able to reduce procedural times, it will have to be combined with other management strategies to increase the number of procedures per theatreday.
Included studies suggested that the use of the Prostar XL device might reduce time to discharge and time to ambulation, although, in most cases, these reductions were not statistically significant, and these two outcomes are susceptible to bias. Therefore, the extent to which the Prostar XL could contribute to timesavings with these outcomes is still unclear. If this is borne out by further studies, such timesavings could be economically important in terms of reduced resource requirement by patients. These timesavings have the potential to significantly benefit patients, by reducing the time they spend immobile and in the hospital, and reduce resource use as well as potentially improving quality of life. Reductions in patient length of stay, particularly in surgical recovery wards, can lead to considerable cost savings for hospitals. Time to ambulation determines the time period over which patients require intensive monitoring and care by medical staff, and, therefore, reductions in time to ambulation may lead to reductions in staff resource use and costs.
Two studies included in this article indicated a potential for costsavings with use of the Prostar XL. One study showed a reduction in total costs, 12 while the second study showed costs were higher with the Prostar XL. 22 It was clear from these studies that some costs (operating room and hospitalisation costs) may be reduced with device use, in agreement with the results on time-related outcomes, while others are increased (such as cost of materials for procedures). More research into this would be beneficial to determine whether the Prostar XL is indeed associated with a reduction in total medical costs of the endovascular procedures in which it is used. 12, 22 It should be emphasised that no evidence is currently available on the cost-effectiveness of the Prostar XL device compared with surgical cutdown; hence, the end costs may vary with differences in the technique and experience of the surgeons using the device. This is especially the case during the learning curve period, as success is dependent upon operator experience. 27 No significant difference between the Prostar XL and surgical cut-down was shown with regard to complication rates. Meta-analysis, along with some individual studies, indicated a lower risk but this was not significant, suggesting further data are needed to confirm this finding. Limited data were available to compare haemorrhage rates. Transfusion rates were similar or slightly lower with the Prostar XL. Only one study provided comparative data for haematoma incidence; the rates were similar for the Prostar XL and surgical cut-down. 23 Thus, overall, the Prostar XL is at least as safe as surgical cut-down in terms of haemorrhage and haematoma.
These results are consistent with findings of a recent review of vascular closure devices, which identified that there was no reduction in complication rates with these devices. 25 Similarly, a systematic review of percutaneous endovascular aneurysm repair performed mostly with the Prostar XL found that the device was associated with a low access-related complication rate compared with openaccess endovascular aneurysm repair. 26 The safety findings of this review are also in agreement with results published in 2009 from a large-scale prospective observational study investigating the safety of femoral artery closure using the Prostar XL in conjunction with the preclose technique, where the investigators report that Prostar XL is safe and associated with minimal early and late complications. 27 It should also be noted that percutaneous closure devices such as the Prostar XL might have other advantages over surgical cut-down. First, the smaller scar reaction at the level of the groin increases the potential for repeat puncture of the femoral artery, allowing further vascular access when necessary. Second, the complications associated with use of the Prostar XL device, whilst similar in frequency to the rate of complications associated with surgical cut-down, can differ markedly in their seriousness and ease of resolution.
There are of course limitations to this review. Much of the data are derived from small-scale uncontrolled observational studies. There were differences between studies in the patient population, type of endovascular procedures performed and the reporting and definition of relevant outcomes; hence, whilst there is a large literature base supporting the pooling of data from observational studies, it is important to interpret the results of such pooling with caution.
Further, in this article, we relied on the data reported in the literature, rather than using patient-level data. These limitations necessarily limit the confidence of the conclusions drawn. Further, higher-powered controlled studies would be beneficial in confirming the data reported here, although there are considerable, well-recognised difficulties in performing large-scale controlled studies in the field of vascular surgery. In addition, further studies based on increased experience in individual institutions with the Prostar XL may be beneficial. With all new procedures, there is a 'learning curve' effect during which potential benefits such as time savings may not be apparent. Therefore, further studies of long-term use are necessary to quantify benefits, which may be apparent after the plateau of the learning curve. 12, 16 Conclusion Evidence from published studies support the idea that closure of femoral arterial access sites of size 10e24 Fr with a device (the Prostar XL with the preclose technique) is as safe and effective as surgical cut-down. There are considerable limitations in the evidence base, with most studies being small-scale uncontrolled studies, and therefore there is considerable uncertainty in the results. However, although further research is clearly needed to compare the Prostar XL with surgical cut-down, the current evidence base suggests that there is the possibility that use of the device could result in clinically meaningful savings in procedural time, patient recovery time and patient length of stay, which may lead to improved safety outcomes and reduced resource use.
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